Table 2.
Plasma levels of IL-8, macrophage inflammatory protein-1α (MIP-1α) and monocyte chemotactic protein-1 (MCP-1) in 25 renal transplant recipients at different time intervals and in 10 controls (data are given as medians and ranges)
| Baseline | Disease/peak antigenaemia | Follow up | |
|---|---|---|---|
| IL-8 (pg/ml): | |||
| Controls | 0 (0–0) | ||
| Group A | 3·4 (0–13)1,2,3 | 16·1 (0–36·8)* | 0 (0–14·1)† |
| Group B | 0 (0–0) | 0 (0–6·7) | 3·2 (0–6·4) |
| Group C | 0 (0–21·5) | 0 (0–0) | 0 (0–0) |
| MIP-1α (pg/ml): | |||
| Controls | 16·4 (11·9–21·4) | ||
| Group A | 10·7 (5·4–23·9)1,2 | 25·2 (7·6–34·3)* | 12·1 (0–18·4)† |
| Group B | 19·8 (16·5–34) | 28 (14·8–31·1) | 25·6 (15·3–28·8) |
| Group C | 17·2 (14·6–24·7) | 18·2 (17·1–25) | 19·5 (14·3–27) |
| MCP-1 (pg/ml): | |||
| Controls | 92 (19–151) | ||
| Group A | 366 (220–778)1 | 771 (430–1976)** | 474 (138–696)† |
| Group B | 424 (272–564)1 | 604 (450–960) | 737 (492–988) |
| Group C | 330 (210–736)1 | 485 (270–710)* | 419 (151–558) |
Group A, patients with cytome galovirus (CMV) disease; Group B, patients with asymptomatic CMV infection; group C, patients withour CMV infection.
1
P < 0·05 versus controls
2
P < 0·05 versus group C
3
P < 0·05 versus group B.
*
P < 0·05 versus controls
**
P < 0·05 versus time 0.
†
P < 0·05 versus time 1
†P < 0·05 versus time 1 in the same group.0